A Double-Blind, Randomized, Placebo-Controlled Phase 3 Noninferiority Study of Darbepoetin Alfa for Anemia in Advanced NSCLC

被引：3
|
作者：
Nagarkar, R. [1 ]
Gascon, P. [2 ]
Smakal, M. [3 ]
Syrigos, K. [4 ]
Barrios, C. [5 ]
Cardenas Sanchez, J. [6 ]
Zhang, L. [7 ]
Tomita, D. [8 ]
Park, J. [8 ]
Brandao, C. De Oliveira [8 ]
机构：
[1] Curie Manavata Canc Ctr, Nasik, Maharashtra, India
[2] Barcelona Univ, Hosp Clin, Barcelona, Spain
[3] Nh Hosp AS, Nemocn Horovice, Horovice, Czech Republic
[4] Athens Sch Med, Dept Med 3, Athens, Greece
[5] Hosp Canc Mae Deus, Med Oncol, Porto Alegre, RS, Brazil
[6] Ctr Med Colima, Colima, Mexico
[7] Sun Yat Sen Univ, Canc Ctr, East Guangzhou, Peoples R China
[8] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
overall survival; darbepoetin alfa; chemotherapy-induced anemia;
D O I：
10.1016/j.jtho.2018.08.325
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.05
引用
收藏
页码：S359 / S359
页数：1
相关论文
共 50 条
  • [1] A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC
    Gascon, Pere
    Nagarkar, Rajnish
    Smakal, Martin
    Syrigos, Konstantinos N.
    Barrios, Carlos H.
    Cardenas Sanchez, Jesus
    Zhang, Li
    Henry, David H.
    Gordon, David
    Hirsh, Vera
    Kubota, Kaoru
    Orlov, Sergey
    Thomas, Gary
    Steinmetz, Tilman
    Kang, Jin-Hyoung
    Tomita, Dianne K.
    Fleishman, Alexander N.
    Park, Joseph K.
    Brandao, Cisio De Oliveira
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (02) : 190 - 202
  • [2] Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia
    Taylor, K
    Ganly, P
    Charu, V
    DiBenedetto, J
    Kracht, K
    Rossi, G
    Hernandez, E
    BLOOD, 2005, 106 (11) : 992A - 993A
  • [3] Results from a phase 3, randomized, double-blind, placebo-controlled study of darbepoetin alfa for the treatment of anemia in cancer patients not receiving chemotherapy or radiotherapy
    Glaspy, J. A.
    Smith, R. E.
    Aapro, M.
    Ludwig, H.
    Pinter, T.
    Smakal, M.
    Ciuleanu, T.
    Chen, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 136 - 136
  • [4] Correction of Anemia in the Frail Elderly (CAFE): Results of a Randomized, Double-Blind, Placebo-Controlled Study with Darbepoetin Alfa in Elderly Patients with Chronic Unexplained Anemia
    Loaiza-Bonilla, Arturo
    Artz, Andrew
    Salerno, Francis
    Leng, Sean X.
    Yeh, Shing-Shing
    Biedenbender, Rex
    Gravenstein, Stefan
    Loera, Jose
    Geloo, Zeba Shaheen
    Ershler, William B.
    BLOOD, 2012, 120 (21)
  • [5] Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:: a randomized, double-blind, placebo-controlled study
    Hedenus, M
    Adriansson, M
    San Miguel, J
    Kramer, MHH
    Schipperus, MR
    Juvonen, E
    Taylor, K
    Belch, A
    Altés, A
    Martinelli, G
    Watson, D
    Matcham, J
    Rossi, G
    Littlewood, TJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (03) : 394 - 403
  • [6] Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
    Vansteenkiste, J
    Pirker, R
    Massuti, B
    Barata, F
    Font, A
    Fiegl, M
    Siena, S
    Gateley, J
    Tomita, D
    Colowick, AB
    Musil, J
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (16) : 1211 - 1220
  • [7] Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study
    Smith, Robert E.
    Aapro, Matti S.
    Ludwig, Heinz
    Pinter, Tamas
    Smakal, Martin
    Ciuleanu, Tudor E.
    Chen, Li
    Lillie, Tom
    Glaspy, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) : 1040 - 1050
  • [8] Re: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
    VanAudenrode, M
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (10) : 761 - 762
  • [9] Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia
    Hernandez, Enrique
    Ganly, Peter
    Charu, Veena
    DiBenedetto, Joseph
    Tomita, Dianne
    Lillie, Tom
    Taylor, Kerry
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (09) : 2109 - 2120
  • [10] Effect of darbepoetin alfa on physical function in patients undergoing surgery for colorectal cancer - A randomized, double-blind, placebo-controlled study
    Norager, C. B.
    Jensen, M. B.
    Madsen, M. R.
    Qvist, N.
    Laurberg, S.
    ONCOLOGY, 2006, 71 (3-4) : 212 - 220
12345